Endothelin receptor antagonist: Difference between revisions
Jump to navigation
Jump to search
Matt Pijoan (talk | contribs) m (Protected "Endothelin receptor antagonist": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +)) |
||
| Line 1: | Line 1: | ||
{{CMG}} | {{CMG}} | ||
__NOTOC__ | __NOTOC__ | ||
A '''endothelin receptor antagonist''' ('''ERA''') is a [[medication|drug]] which blocks [[endothelin]] receptors. | A '''endothelin receptor antagonist''' ('''ERA''') is a [[medication|drug]] which blocks [[endothelin]] receptors. | ||
Latest revision as of 02:15, 9 August 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
A endothelin receptor antagonist (ERA) is a drug which blocks endothelin receptors.
Two main kinds of ERAs exist:
- selective ERA (e.g. sitaxsentan), which affect endothelin A.
- dual ERAs,(e.g. bosentan) which affect both endothelin A and B .[1]
See also
References